Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis

NCT02022215 is registered in ClinicalTrials.gov with Meiji Seika Pharma Co., Ltd. as lead sponsor.

NCT NCT02022215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02022215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2013
Completion date
March 1, 2016
Enrollment
304 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

onychomycosis